表紙
市場調查報告書

焦點市場分析:諾羅病毒

Market Spotlight: Norovirus

出版商 Datamonitor Healthcare 商品編碼 633157
出版日期 內容資訊 英文 22 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
焦點市場分析:諾羅病毒 Market Spotlight: Norovirus
出版日期: 2019年12月05日內容資訊: 英文 22 Pages
簡介

就全球來看,每五件急性腸胃炎中就有約一件與諾羅病毒有關。諾羅病毒引發的腸胃炎,每年約6億8,500萬件。

本報告提供全球諾羅病毒市場調查,彙整疾病的背景·概要,治療方法,開發平台治療藥概要,臨床試驗狀況等資料。

概要

要點

疾病的背景

治療

  • 疫苗開發的課題

流行病學

  • 諾羅病毒爆發大流行

開發平台藥物

臨床實驗形勢

  • 贊助商:地位
  • 贊助商:不同階段
  • 近幾年的活動

參考資料

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0183940

This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, key upcoming events, and an epidemiological overview.

Key Takeaways

Worldwide, about one out of every five cases of acute gastroenteritis is associated with norovirus. Norovirus is responsible for approximately 685 million cases of gastroenteritis every year.

Globally, norovirus is estimated to cause approximately 200,000 deaths annually, including an estimated 50,000 child deaths, mainly in developing countries.

The largest proportion of industry-sponsored drugs in active clinical development for norovirus are in Phase I. All clinical candidates currently in the pipeline for norovirus are vaccines. These drugs are administered via the oral, intranasal, and intramuscular routes.

High-impact upcoming events for drugs in the norovirus space comprise topline Phase IIb trial results for Monovalent Norovirus VLP Vaccine, and topline Phase II trial results for VXA-G1.1-NN.

The overall likelihood of approval of a Phase I antiviral asset is 14.2%, and the average probability a drug advances from Phase III is 74.8%. Drugs, on average, take 8.7 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for norovirus have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.

The US has a substantial lead in the number of norovirus clinical trials globally.

Takeda has the highest number of completed clinical trials for norovirus, with 12 trials.

Takeda leads the industry sponsors with the highest overall number of clinical trials for norovirus.

TABLE OF CONTENTS

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

8 TREATMENT

9 EPIDEMIOLOGY

9 Norovirus outbreaks

9 Challenges for vaccine development

11 PIPELINE DRUGS

15 KEY UPCOMING EVENTS

16 PROBABILITY OF SUCCESS

17 CLINICAL TRIAL LANDSCAPE

18 Sponsors by status

19 Sponsors by phase

20 BIBLIOGRAPHY

21 APPENDIX

LIST OF FIGURES

  • 11 Figure 1: Overview of pipeline drugs for norovirus in the US
  • 11 Figure 2: Pipeline drugs for norovirus, by company
  • 11 Figure 3: Pipeline drugs for norovirus, by drug type
  • 12 Figure 4: Pipeline drugs for norovirus, by classification
  • 15 Figure 5: Key upcoming events in norovirus
  • 16 Figure 6: Probability of success in the norovirus pipeline
  • 17 Figure 7: Clinical trials in norovirus
  • 17 Figure 8: Top 10 drugs for clinical trials in norovirus
  • 18 Figure 9: Top 10 companies for clinical trials in norovirus
  • 18 Figure 10: Trial locations in norovirus
  • 19 Figure 11: Norovirus trials status
  • 19 Figure 12: Norovirus trials sponsors, by phase

LIST OF TABLES

  • 13 Table 1: Pipeline drugs for norovirus in the US
Back to Top